Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Investigating a novel trans-synaptic complex of molecules independently-implicated in ASD
FY 2023-24
Summary
G protein-coupled receptors are the target of ~34% of all approved drugs. Recently, the accepted pharmacological principles of GPCRs have been critically altered by the discovery of trans-synaptic modulatory complexes involving synaptic adhesion molecules and GPCRs: specifically, a subset of metabotropic glutamate receptors (mGluRs). Of all mGluRs, mGluR5 stands out as the most encouraging target for neurological diseases, including autism spectrum disorder (ASD). In search of novel trans-complexes, I mined datasets for potential binding partners of postsynaptic mGluR5, focusing on synaptic adhesion molecules, and surprisingly found presynaptic neurexin-1 (NRXN1): a prominent molecule in ASD. Therefore, I hypothesize NRXN1 is a novel trans-synaptic modulator of mGluR5 and this interaction may provide novel therapeutic strategies for ASD drug design. I have three objectives:
1. Validate and characterize the trans-synaptic interaction between mGluR5 and NRXN1
2. Investigate alterations in accepted pharmacology of mGluR5 via NRXN1 in trans
3. Translate mGluR5-NRXN1 discoveries to a new trans-synaptic model
In short, I will validate this novel interaction using transcellular co-immunoprecipitations, characterize the pharmacological consequence of this transcellular interaction utilizing advanced GPCR signalling assays, and develop a new synaptic model to translate these findings into synaptogenic potential and trans-synaptic modulation of mGluR5 in induced pluripotent stem cell-derived neurons. This research will characterize a new trans-synaptic mechanism in neurobiology, while connecting two molecules independently implicated in ASD. This may illuminate new mechanisms underlying ASD etiology with potential for guiding future pharmacological therapeutic strategies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
521692
Name
Baskerville Kaden R
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating a novel trans-synaptic complex of molecules independently-implicated in ASD
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autism Spectrum Disorder (Asd); G-Protein Coupled Receptor (Gpcr); Induced Pluripotent Stem Cells; Metabotropic Glutamate Receptor 5 (Mglur5); Molecular Biology; Neurexin-1 (Nrxn1); Neuropharmacology; Synapse; Synaptic Adhesion Molecule; Trans-Synaptic Signalling
Abstract
G protein-coupled receptors are the target of ~34% of all approved drugs. Recently, the accepted pharmacological principles of GPCRs have been critically altered by the discovery of trans-synaptic modulatory complexes involving synaptic adhesion molecules and GPCRs: specifically, a subset of metabotropic glutamate receptors (mGluRs). Of all mGluRs, mGluR5 stands out as the most encouraging target for neurological diseases, including autism spectrum disorder (ASD). In search of novel trans-complexes, I mined datasets for potential binding partners of postsynaptic mGluR5, focusing on synaptic adhesion molecules, and surprisingly found presynaptic neurexin-1 (NRXN1): a prominent molecule in ASD. Therefore, I hypothesize NRXN1 is a novel trans-synaptic modulator of mGluR5 and this interaction may provide novel therapeutic strategies for ASD drug design. I have three objectives:
1. Validate and characterize the trans-synaptic interaction between mGluR5 and NRXN1
2. Investigate alterations in accepted pharmacology of mGluR5 via NRXN1 in trans
3. Translate mGluR5-NRXN1 discoveries to a new trans-synaptic model
In short, I will validate this novel interaction using transcellular co-immunoprecipitations, characterize the pharmacological consequence of this transcellular interaction utilizing advanced GPCR signalling assays, and develop a new synaptic model to translate these findings into synaptogenic potential and trans-synaptic modulation of mGluR5 in induced pluripotent stem cell-derived neurons. This research will characterize a new trans-synaptic mechanism in neurobiology, while connecting two molecules independently implicated in ASD. This may illuminate new mechanisms underlying ASD etiology with potential for guiding future pharmacological therapeutic strategies.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Baskerville, Kaden R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~